The currently ongoing TG-1101 Phase 1 trial in NHL patients will have data in mid-2013, and begin to enroll Phase 2 part patients, as well, with more data expected at the ASH conference in 2013, says the analyst.
The news results from a risky gambit by drugmaker AstraZeneca (nyse: AZN - news - people ) to test the new medicine, Cerovive, in a 1, 700-patient Phase III clinical trial before proof of human efficacy was available.